Braveheart Bio
PrivateLast Round
IPO
Aug 5, 2026
Est. Valuation
$1.4B
Total Funding Raised
$185M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Braveheart Bio is a biotechnology company developing novel therapeutics for hypertrophic cardiomyopathy and related cardiovascular conditions.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Braveheart Bio Comparables
Compare Braveheart Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Sanofi | 80% | |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 78% | |
| Cytokinetics, Incorporated | 77% |
Braveheart Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Aug 5, 2026 | ||||
| Series A | Nov 5, 2025 |
Key People
Founding team and executive leadership
Braveheart Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Andreessen Horowitz | Series A |
| Enavate Sciences | Series A |
| Forbion | Series A |
| Fidelity Management & Research Company | IPO |
| OrbiMed | Series A |
| Frazier Life Sciences | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 5, 2026
$383M raised with Fidelity Management & Research Company participating.
- Jul 18, 2026
Grew 44% QoQ, from 27 to 39 employees.
Recent news
Latest coverage and updates
- is_developingSep 18, 2026
Braveheart is developing therapies for hypertrophic cardiomyopathy on Sep 19th '26.
- attends_eventSep 16, 2026
Braveheart will attend event Stifel Virtual Cardiometabolic Forum on Sep 30th '26.
- attends_eventSep 1, 2026
Braveheart will attend event Cantor Global Healthcare Conference on Sep 9th '26.
- receives_financingAug 6, 2026
Braveheart received financing of $383M in IPO on Aug 6th '26.
- goes_publicJul 15, 2026
Braveheart Bio is planning to go public.
Braveheart Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Braveheart Bio's valuation, stock price, and market status.
Is Braveheart Bio a public or private company?
Braveheart Bio is a private company.
What is the current stock price of Braveheart Bio?
Braveheart Bio is a private company with no public stock price. No recent secondary market data is available.
How much is Braveheart Bio worth (valuation)?
Valuation information for Braveheart Bio is not publicly available.
Can I buy Braveheart Bio stock?
Braveheart Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Braveheart Bio's last funding round?
Braveheart Bio's most recent funding round was Series A on November 5, 2025.
Who are the main investors in Braveheart Bio?
Key investors in Braveheart Bio include Andreessen Horowitz, OrbiMed.
Will Braveheart Bio IPO soon?
No public IPO plans have been announced for Braveheart Bio.
How can I track Braveheart Bio secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Braveheart Bio's secondary market activity and sign up for updates.